Research Projects

Immediate past and future research projects include the multipaper expert consensus statement on pediatric PH, normal reference values for non-invasive diagnostics, a survey and subsequent patient registry on children with both chronic (parenchymal) lung disease and pulmonary hypertension (e.g. bronchopulmonary dysplasia). Additional research projects are already in preparation or can be proposed by PVD network members.

Learn more

Publications

In the last 30 years, rapid, accelerated knowledge gain due to an increasing number of publications on pathobiology and clinical trials have led to more tailored (“personalized”), goal oriented treatment modalities for PAH. From 2015-2020, new insights into metabolic dysregulation and previously unknown gene mutations, and high impact, high volume, longterm randomized controlled trials (RCT) using combined outcomes such as “first morbidity and mortality”, have been published, leading to the approval of more PAH drugs acting on previously known pathways. However, prospective studies in children and adolescents with PAH are largely lacking (only one RCT published by May, 2020). In 2020, the EPPVDN published the two first prospective observational studies on the use of selexipag (Hansmannn G et al., J Heart Lung Transpl, 2020; doi:…..) and macitentan (Schweintzger S et al. Cardivasc Diagn Ther, 2020; doi:….).

Learn more

Meetings & Workshops

On April 7, 2016, the PVD Network conducted the worldwide first hands-on workshop on pediatric PH. The workshop included an introductory talk on echocardiography by Prof. Martin Köstenberger, hands-on teaching with live cases in the echo and cath labs, an ECMO circuit and specific ICU issues, including iNO and HFOV. Next day our PH Symposium took place in Hannover. Future PH workshops and scientific PH meetings are in preparation.

Learn more

PVD Network Videos

For example: Video summary of the PAH-Genetics abstract by Dr. Juha Koskenvuo – presented at the Pulmonary Hypertension Symposium – Update 2016 in Hannover, Germany.

More Videos
More Videos

Research on PH and Heart Failure

In the last 30 years, rapid, accelerated knowledge gain due to an increasing number of publications on pathobiology and clinical trials have led to more tailored (“personalized”), goal oriented treatment modalities for PAH. New insights into metabolic dysregulation and previously unknown gene mutations, and high impact, high volume, longterm randomized controlled trials (RCT) using combined outcomes such as “first morbidity and mortality”, have been published, leading to the approval of more PAH drugs acting on previously known pathways. However, prospective studies in children and adolescents with PAH are largely lacking.

The number of publications addressing experimental therapies in PAH began to increase in 1995 after landmark studies in human PAH tissues and randomized controlled clinical PAH trials had been published.

Legend:

To evaluate the number of publications addressing experimental therapies in pulmonary arterial hypertension (PAH), the search engine Web of Science, which is a citation database of research literature, was used (www.webofknowledge.com). In the advanced search options we refined our outline query to Pulmonary Arterial Hypertension AND therapies and analyzed the Number of publications within the years 1990 and 2019.

In the last 30 years, rapid, accelerated knowledge gain due to an increasing number of publications on pathobiology and clinical trials have led to more tailored (“personalized”), goal oriented treatment modalities for PAH. New insights into metabolic dysregulation and previously unknown gene mutations, and high impact, high volume, longterm randomized controlled trials (RCT) using combined outcomes such as “first morbidity and mortality”, have been published, leading to the approval of more PAH drugs acting on previously known pathways. However, prospective studies in children and adolescents with PAH are largely lacking.

The number of publications addressing experimental therapies in PAH began to increase in 1995 after landmark studies in human PAH tissues and randomized controlled clinical PAH trials had been published.

Legend:

To evaluate the number of publications addressing experimental therapies in pulmonary arterial hypertension (P